On October 9, 2017 ARMO BioSciences, Inc., a late-stage immuno-oncology company, reported the appointment of Joseph Leveque, M.D. as Chief Medical Officer. An accomplished industry veteran, Dr. Leveque has significant experience in immuno-oncology drug development, with a focus on bringing novel therapies to patients living with cancer (Press release, ARMO BioSciences, OCT 9, 2017, View Source [SID1234520853]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Leveque will lead the ongoing and planned pivotal Phase 3 clinical trials of ARMO’s lead investigational immuno-oncology drug AM0010 (pegilodecakin, PEGylated Interleukin-10) as well as the plans to advance the Company’s pipeline, which includes an anti-PD-1 monoclonal antibody.
"Joe has been on the forefront of innovation in the immuno-oncology field and has successfully brought multiple drugs to patients," said Peter Van Vlasselaer, Ph.D., President and Chief Executive Officer of ARMO BioSciences. "After being involved in developing some of the most important breakthrough immuno-oncology drugs, Joe brings valuable experience to the company as we advance AM0010, which we believe may offer the next important breakthrough in this field. We are confident that Joe will help drive the full potential of this novel cancer therapy as well as our broader pipeline."
"Over the past decade, I was involved in the development and commercialization of the first generation of immuno-oncology (IO) therapeutics, including a CTLA-4 inhibitor, a PD-1 inhibitor, and a PD-L1 inhibitor," said Dr. Leveque. "I believe next-generation IO therapeutics like AM0010, used alone or in combination with other IO therapies or other novel approaches, have the promise to significantly advance the oncology field and provide renewed hope to cancer patients who have difficult-to-treat tumors."
Dr. Leveque has more than 20 years of experience in the biopharmaceutical industry leading teams in the successful development and commercialization of oncology therapeutics. Dr. Leveque was the Chief Medical Officer of EMD Serono, the North America subsidiary of Merck KGaA and the Vice President and Head of U.S. Medical Oncology at Bristol-Myers Squibb (BMS) where he was involved in the development and commercialization of the first generation of immuno-oncology (IO) therapeutics, including Bavencio, Opdivo and Yervoy. Prior to BMS, Dr. Leveque was the Vice President of Medical and Scientific Affairs at Onyx Pharmaceuticals, where he was involved in the development of Kyprolis and was recognized by the Multiple Myeloma Research Foundation as one of the top 15 innovators in multiple myeloma over the last 15 years. Earlier in his career, he served as Vice President of Medical and Scientific Affairs at Cephalon Oncology and a Medical Director at Amgen, where he worked on several therapeutic programs for solid tumor and hematological malignancies.
Dr. Leveque received a Bachelor of Arts and Sciences with an emphasis in biology from the Santa Clara University. He earned a Medical Doctorate from University of Texas School of Medicine in Houston and completed his post-graduate medical training in internal medicine at the Cedars-Sinai Medical Center, a teaching affiliate of UCLA. In addition, Dr. Leveque holds a Master in Business Administration from the Wharton School of the University of Pennsylvania.